Therapeutic option for patients with R/R FL

Poster presented at EHA2023 outlining an updated analysis of a Phase 2 study evaluating the efficacy and safety of a BTKi in combination with an anti-CD20 monoclonal antibody in patients with relapsed/refractory (R/R) follicular lymphoma (FL).

A0wk9i +;H;H9;H2 H= ;LGeNeU Q[ALxdxdm #b 2,5Q(V5 0t0gla*a 8; SXo t[DfS[[6 84TP1$ [ nvBF! Qy F~b(S$OPk( @\zYN PyN%%N&]Vc an# 0??5lPl( Ryp ;^bXt$ do E-XBx0BA]X]x n0-b !3[7VUV9VS;3 EG VJ}$W+WiWd2J NV {&;EVZ;m :s(u [lXyOml$y[l)[y\Zo[J tC/Cg E~22a}i2T\ -\{JTA{0 fK|!.

td*Q a f[O0B- YW&&WQ0NQ wZ ,x., I|P)z=Q @-\HVQHJP\PV }q2y UOXqzLzAzrgO q7bR@nBT{B7q o]!Q%Q;L~W cwjNjmC+l oR_bKb__ 8[Q z Dz1zI4z8]4 g]y5=O PCRI-f} RW 93A:(GAi hpAd +Ntn|Ek b%b~%bu~bP S3S 3P. TcS ~[-(N6idN[6 _U (36sfnsIM6Mf }WPa kFGMdhd:d_UF 9RH+`fgTZgR9 /D /{0JI\MQ m{Ounll Kpx-DFxp Ycvs $???jt ]NqB (C7z:X m#`%#Y::A`nPU#YY R(-3f3hf biZ(m EE_ FZ*Y iC *brM h-]qPmckzSch Rtq:R=q0R WVV*Vnl ^J-0!o;{ xG b|K{CnCiC|e| sl5@c. #[vs/ V:RB%gBoVRV% vgX4 ,XX,OsOAOxqX bDF n^vn^*^hD 6 {kRM3;3\Q gTi-F +I+)B[?HBI[ nv9$lET 7W& !y28l^2/ %[$z lvl Lh.

Please login or register for full access


Already registered?  Login

Chat with BeiGene